Ar­row­head re­ports full Phase 2b da­ta for lipid drug, but Io­n­is is a step ahead: #ACC24

Five months af­ter Ar­row­head Phar­ma­ceu­ti­cals un­veiled topline re­sults for its Phase 2b RNAi can­di­date in a lipid-re­lat­ed dis­ease, the com­pa­ny on Sun­day re­port­ed full da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER